verapamil has been researched along with Intestinal Diseases in 3 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Intestinal Diseases: Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the effect of verapamil on intestinal ischemia and reperfusion (I/R) injury." | 7.70 | Beneficial effects of verapamil on intestinal ischemia and reperfusion injury: pretreatment versus postischemic treatment. ( Fujii, Y; Kataoka, M; Kato, T; Kimura, M; Kuwabara, Y; Narita, K; Okahira, T; Sato, A, 1998) |
| "We studied the effect of verapamil on intestinal ischemia and reperfusion (I/R) injury." | 3.70 | Beneficial effects of verapamil on intestinal ischemia and reperfusion injury: pretreatment versus postischemic treatment. ( Fujii, Y; Kataoka, M; Kato, T; Kimura, M; Kuwabara, Y; Narita, K; Okahira, T; Sato, A, 1998) |
| "Treatment with verapamil, an inhibitor of P-gp, significantly improved the absorption of enrofloxacin in both healthy and infected broilers." | 1.40 | E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ( Bughio, S; Dai, X; Guo, M; Ren, W; Sun, Y; Wang, L; Zhang, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, M | 1 |
| Sun, Y | 1 |
| Zhang, Y | 1 |
| Bughio, S | 1 |
| Dai, X | 1 |
| Ren, W | 1 |
| Wang, L | 1 |
| Kimura, M | 1 |
| Kataoka, M | 1 |
| Kuwabara, Y | 1 |
| Sato, A | 1 |
| Kato, T | 1 |
| Narita, K | 1 |
| Okahira, T | 1 |
| Fujii, Y | 1 |
| Schultz, HS | 1 |
| Vernon, B | 1 |
3 other studies available for verapamil and Intestinal Diseases
| Article | Year |
|---|---|
E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers.
Topics: Animals; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Sub | 2014 |
Beneficial effects of verapamil on intestinal ischemia and reperfusion injury: pretreatment versus postischemic treatment.
Topics: Animals; Edema; Intestinal Diseases; Intestines; Ischemia; Magnetic Resonance Spectroscopy; Male; Ra | 1998 |
Intestinal pseudo-obstruction related to using verapamil.
Topics: Aged; Female; Gastrointestinal Motility; Humans; Intestinal Diseases; Intestinal Pseudo-Obstruction; | 1989 |